NASDAQ:CTXR - Citius Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.46 +0.11 (+8.15 %)
(As of 09/19/2018 02:13 PM ET)
Previous Close$1.44
Today's Range$1.44 - $1.46
52-Week Range$1.12 - $5.49
Volume500 shs
Average Volume88,922 shs
Market Capitalization$22.68 million
P/E RatioN/A
Dividend YieldN/A
Beta3.92
Citius Pharmaceuticals logoCitius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok product, which has completed Phase IIb clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido product, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids. It has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products in United States, Canada, and Mexico. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Receive CTXR News and Ratings via Email

Sign-up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CTXR
CUSIPN/A
Phone908-967-6677

Debt

Debt-to-Equity RatioN/A
Current Ratio1.29
Quick Ratio1.29

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.66 per share
Price / Book0.55

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-10,380,000.00
Net MarginsN/A
Return on Equity-54.80%
Return on Assets-49.55%

Miscellaneous

Employees7
Outstanding Shares16,200,000
Market Cap$22.68 million

Citius Pharmaceuticals (NASDAQ:CTXR) Frequently Asked Questions

What is Citius Pharmaceuticals' stock symbol?

Citius Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTXR."

When did Citius Pharmaceuticals' stock split? How did Citius Pharmaceuticals' stock split work?

Citius Pharmaceuticals's stock reverse split before market open on Friday, June 9th 2017. The 1-15 reverse split was announced on Thursday, June 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 8th 2017. An investor that had 100 shares of Citius Pharmaceuticals stock prior to the reverse split would have 7 shares after the split.

How were Citius Pharmaceuticals' earnings last quarter?

Citius Pharmaceuticals Inc (NASDAQ:CTXR) posted its quarterly earnings results on Tuesday, August, 14th. The company reported ($0.19) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.32) by $0.13. View Citius Pharmaceuticals' Earnings History.

What price target have analysts set for CTXR?

1 brokers have issued 12 month price objectives for Citius Pharmaceuticals' stock. Their predictions range from $11.00 to $11.00. On average, they expect Citius Pharmaceuticals' share price to reach $11.00 in the next year. This suggests a possible upside of 653.4% from the stock's current price. View Analyst Price Targets for Citius Pharmaceuticals.

What is the consensus analysts' recommendation for Citius Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Citius Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Citius Pharmaceuticals.

Who are some of Citius Pharmaceuticals' key competitors?

Who are Citius Pharmaceuticals' key executives?

Citius Pharmaceuticals' management team includes the folowing people:
  • Mr. Leonard L. Mazur, Exec. Chairman & Sec. (Age 73)
  • Mr. Myron Z. Holubiak, Pres, CEO & Director (Age 71)
  • Mr. Jaime Bartushak, CFO & Chief Accounting Officer (Age 50)
  • Mr. Gary F. Talarico, Exec. VP of Operations (Age 63)
  • Mr. Andrew Scott, VP of Corp. Devel.

Has Citius Pharmaceuticals been receiving favorable news coverage?

Media stories about CTXR stock have trended somewhat positive this week, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Citius Pharmaceuticals earned a news and rumor sentiment score of 0.18 on Accern's scale. They also gave media stories about the company an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View Recent Headlines for Citius Pharmaceuticals.

How do I buy shares of Citius Pharmaceuticals?

Shares of CTXR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Citius Pharmaceuticals' stock price today?

One share of CTXR stock can currently be purchased for approximately $1.46.

How big of a company is Citius Pharmaceuticals?

Citius Pharmaceuticals has a market capitalization of $22.68 million. Citius Pharmaceuticals employs 7 workers across the globe.

How can I contact Citius Pharmaceuticals?

Citius Pharmaceuticals' mailing address is 11 Commerce Drive First Floor, Cranford NJ, 07016. The company can be reached via phone at 908-967-6677.


MarketBeat Community Rating for Citius Pharmaceuticals (NASDAQ CTXR)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  62 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  134
MarketBeat's community ratings are surveys of what our community members think about Citius Pharmaceuticals and other stocks. Vote "Outperform" if you believe CTXR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTXR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel